According to a multi-center clinical trial led by researchers at the Stanford University School of Medicine, a new type of immunotherapy seems to be safe for patients with blood cancer called non-Hodgkin’s lymphoma.
The therapy combines experimental antibodies developed by researchers at Stanford University and commercially available anti-cancer antibodies to rituximab. It referred Hu5F9-G4 experimental protein antibody blockade of CD47 , of CD47 suppressed immune attack against cancer cells. The combination of two antibodies is used to treat people with two types of 非ホジキンリンパ腫: diffuse large B- cell lymphoma and follicular lymphoma.
2010年、スタンフォード幹細胞生物学・再生医学研究所所長アービング・ワイスマン医学博士率いる研究者らは、ほぼすべてのがん細胞がCD47と呼ばれるタンパク質で覆われており、「私を食べないでください」シグナルを発することができることを示した。マクロファージに。
Weissman and colleagues later developed an antibody called Hu5F9-G4 that blocks the CD47 protein and encourages macrophages to engulf cancer cells. Rituximab is an antibody that has been shown to amplify the positive ” eat me ” signal. The combination of rituximab and Hu5F-G4 has previously been shown to be effective against human cancer in animal models, but this is the first published result of clinical trials of the therapy in humans.
試験に参加した22人の患者のうち、11人の患者は臨床癌を大幅に減少させ、8人の患者は癌の兆候をすべて除去した。 治験に参加した他のXNUMX人の患者は治療に反応せず、病気の進行により死亡した。 研究者らは、参加者には軽度の副作用しか生じていないことを観察しました。
Dr. Saul A. Rosenberg , a lymphoma professor , said that such a potential new 免疫療法 is very exciting. This is the first time that an antibody that can activate macrophages to fight cancer is used, and it seems to be safe for use in humans.
https://medicalxpress.com/news/2018-10-anti-cd47-cancer-therapy-safe-small.html
